NCT02356302View on ClinicalTrials.gov

Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
HIV Infections
Interventions
DEVICE

Vicriviroc (MK-4176) Intravaginal Ring (IVR)

Contains 182 mg vicriviroc (MK-4176).

DEVICE

MK-2048 IVR

Contains 30 mg MK-2048.

DEVICE

MK-2048A IVR

Contains 182 mg vicriviroc (MK-4176) and 30 mg MK-2048.

DEVICE

Placebo IVR

Trial Locations (2)

15213

University of Pittsburgh CRS, Pittsburgh

35294

Alabama CRS, Birmingham

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02356302 - Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048 | Biotech Hunter | Biotech Hunter